Molecular Subtype
Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
CI-CAN-00009223Explore in graph →
Hematologic4 active trials3 evidence items
- NCIt
- C9287
- OncoTree
- AMLCBFBMYH11
- DOID
- 0081084
- UMLS CUI
- C5395080
Loading cancer entity…
Molecular Subtype
CI-CAN-00009223Explore in graph →
Clinical trials
169 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (33)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01822015 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Early Phase 1 | 55 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 29, 2025source: clinicaltrials